Brought to you by 
Sirion takes on US rights to Thea's eye infection gel
06 Feb 2007
Executive Summary
Aiming to introduce a medicine into an antiviral eye treatment market that hasn't seen a new product in more than 20 years, Sirion Therapeutics has received exclusive US development, manufacturing, and marketing rights to a topical ganciclovir gel from fellow ophthalmics firm Laboratoires Thea.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sirion takes on US rights to Thea's eye infection gel
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice